Is the Urine Cannabinoid Level Measured via a Commercial Point-of-Care Semiquantitative Immunoassay a Cannabis Withdrawal Syndrome Severity Predictor?

• Published in: Frontiers in psychiatry Vol. 11; p. 598150
• Main Authors: Claus, Benedikt Bernd, Specka, Michael, McAnally, Heath, Scherbaum, Norbert, Schifano, Fabrizio, Bonnet, Udo
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 03.12.2020
• Subjects: cannabis withdrawal syndrome subtypes; gender effect; inpatient detoxification treatment; protracted withdrawal syndrome; Psychiatry; urinary 11-nor-9-carboxy-delta9-tetrahydrocannabinol; cannabis withdrawal syndrome subtypes; protracted withdrawal syndrome; urinary 11-nor-9-carboxy-delta9-tetrahydrocannabinol; gender effect; inpatient detoxification treatment

Background: For cannabis-dependent subjects, the relationship between cannabis withdrawal syndrome (CWS) severity and the urine cannabinoid concentrations are unclear; we investigated this using a commercial point-of-care (POC) enzyme immunoassay detecting 11-nor-9-carboxy-Delta-9-tetrahydrocannabin...